Documents A to Z

| 1 | 2 | 3 | 4 | 5 | 7 | 8 | 9 | A | B | C | D | E | F | G | H | I | J | L | M | N | O | P | Q | R | S | T | U | V | W | Z

M

New WHO public inspection reports (WHOPIRs) published PDF

M

Newly prequalified active pharmaceutical ingredient (API) PDF

M

Newly prequalified active pharmaceutical ingredient (API) PDF

M

Newly prequalified active pharmaceutical ingredient (API) PDF

M

Newly prequalified active pharmaceutical ingredient (API)

M

Newly prequalified active pharmaceutical ingredient (API)

M

Newly prequalified active pharmaceutical ingredient (API)

M

Newly prequalified active pharmaceutical ingredients (APIs) PDF

M

Newly prequalified active pharmaceutical ingredients (APIs) PDF

M

Nitrosamine concerns for rifapentine and rifampicin - Update and FAQs PDF

M

Nitrosamine Contamination Policy for Finished Pharmaceutical Producs (FPPs) applications PDF

M

NMRAs participating in the WHO collaborative procedure PDF

M

Note on ePI/mobile technologies for product information (9 January 2024) PDF

M

Note on paediatric products in PQT Medicines PDF

M

Note with respect to WHO PQT/MED Recommended Product Information additional to the SRA Approved Product Information for Products Prequalified via the Abridged (SRA) Route PDF

M

Notes on the Design of Bioequivalence Study: Clindamycin (17 February 2024) PDF

M

Notes on the Design of Bioequivalence Study: dapivirine PDF

M

Notes on the Design of Bioequivalence Study: Emtricitabine/Tenofovir Disoproxil Fumarate PDF

M

Notes on the Design of Bioequivalence Study: Emtricitabine/Tenofovir disoproxil fumarate (20 February 2024) PDF

M

Notes on the Design of Bioequivalence Study: etravirine (6 February 2024) PDF

M

Notes on the Design of Bioequivalence Study: Fluconazole (6 February 2024) PDF

M

Notes on the Design of Bioequivalence Study: Gatifloxacin (18 February 2024) PDF

M

Notes on the Design of Bioequivalence Study: Lamivudine/Tenofovir Alafenamide PDF

M

Notes on the Design of Bioequivalence Study: Lamivudine/Tenofovir Alafenamide/Dolutegravir PDF

M

Notes on the Design of Bioequivalence Study: Lamivudine/Tenofovir Disoproxil Fumarate PDF

M

Notes on the Design of Bioequivalence Study: Lamivudine/Tenofovir disoproxil fumarate (18 February 2024) PDF

M

Notes on the Design of Bioequivalence Study: protionamide PDF

M

Notes on the Design of Bioequivalence Study: Sulfamethoxazole/Trimethoprim/Isoniazid/Pyridoxine PDF

M

Notes on the Design of Bioequivalence Study: valganciclovir PDF

M

Notes on the design of bioequivalence study: Abacavir PDF

M

Notes on the design of bioequivalence study: abacavir/dolutegravir/lamivudine PDF

M

Notes on the design of bioequivalence study: Abacavir/Lamivudine PDF

M

Notes on the design of bioequivalence study: abacavir/lamivudine/lopinavir/ritonavir PDF

M

Notes on the design of bioequivalence study: albendazole PDF

M

Notes on the design of bioequivalence study: amodiaquine PDF

M

Notes on the design of bioequivalence study: amodiaquine/artesunate PDF

M

Notes on the design of bioequivalence study: amoxicillin PDF

M

Notes on the design of bioequivalence study: Amphotericin B (liposomal) PDF

M

Notes on the design of bioequivalence study: arpraziquantel PDF

M

Notes on the design of bioequivalence study: artemether + lumefantrine PDF

M

Notes on the design of bioequivalence study: artemether/lumefantrine PDF

M

Notes on the design of bioequivalence study: artesunate (rectal) PDF

M

Notes on the design of bioequivalence study: artesunate/mefloquine PDF

M

Notes on the design of bioequivalence study: artesunate/pyronaridine PDF

M

Notes on the design of bioequivalence study: atazanavir/ritonavir PDF

M

Notes on the design of bioequivalence study: azithromycin PDF

M

Notes on the design of bioequivalence study: baloxavir marboxil PDF

M

Notes on the design of bioequivalence study: baricitinib PDF

M

Notes on the design of bioequivalence study: bedaquiline PDF

M

Notes on the design of bioequivalence study: benzathine benzylpenicillin PDF

Recently Updated Documents

TSS 27 - Template for Comments (17 February 2025)

TSS 26 - Template for Comments (17 February 2025)

TSS 25 - Template for Comments (17 February 2025)

TSS 24 - Template for Comments (17 February 2025)

Technical Specifications Series (TSS) 26 - Rapid diagnostic tests to detect Chlamydia trachomatis antigen

WHO Technical Report Series Location

WHO Technical Report Series documents relating to development, production, distribution, inspection and quality control of medicines can be found in the guidelines section of the WHO web pages dealing with quality assurance of medicines. The guidelines most relevant to WHO medicines prequalification are listed and accessible on the WHO Technical Report Series page.